Samsung Electronics Co., Ltd.

Gi Innovation, Inc.

Young Jun Koh

Seung Hyun Lee

Kwang Ho Cheong

Mi Young Cho

Powei Lin

Jae Woong Hwang

Jung Wook Lee

Myoung Hoon Jung

Yeol Ho Lee

Christina Yi

Kak Namkoong

Myung Ho Jang

Su Youn Nam

Min-Kyung Kim

Myoung Ho Jang

Young-Gyu Cho

Jae-woong Hwang

Dan Bee Ha

Kak Nam Koong

Lin Powei

A fusion protein in which an anti-CD73 antibody or an antigen-binding fragment thereof and IL-2 are linked to each other, and the use thereof are disclosed. The fusion protein or dimer thereof contains an anti-CD73 antibody or an antigen-binding fragment thereof and IL-2, and is able to inhibit adenosine production by binding to CD73 of cancer cells, thereby blocking the A2AR and A2BR signaling pathways, thus controlling the tumor microenvironment. Furthermore, the fusion protein or dimer thereof is able to activate immune cells (CD8+ T cells and CD4+ T cells) along with less activation of immunosuppressive cells such as regulatory T cells (Tregs). In addition, IL-2 or a variant thereof in the fusion protein is able to activate immune cells. Therefore, the fusion protein and dimer thereof may be useful for preventing or treating cancer.

Fusion protein comprising anti-CD73 antibody and IL-2, and use thereof

A pharmaceutical composition containing, as active ingredients, a fusion protein including an IL-2 protein and a CD80 protein, and an anticancer agent is disclosed. A fusion protein including a CD80 fragment, an immunoglobulin Fc, and an IL-2 variant, can activate immune cells such as natural killer cells, and at the same time, can control the immune cell regulatory activity of regulatory T cells. In addition, when an anticancer agent is administered in combination with the fusion protein, cancer can be effectively inhibited. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein of an IL-2 protein and a CD80 protein, and an anticancer agent can increase the immune activity in the body and can be effectively utilized not only for cancer but also for an infectious disease, and thus has high industrial potential.

Pharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug

There is provided a pharmaceutical composition for preventing or treating cancer comprising, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor. The fusion protein containing an CD80 fragment, an Fc domain of an immunoglobulin, and an IL-2 variant in an embodiment can activate immune cells such as natural killer cells as well as control the immune cell regulatory activity of regulatory T cells. In addition, the combined administration of the fusion protein and an immune checkpoint inhibitor such as Keytruda known as a PD-1 inhibitor can effectively inhibit cancer. Therefore, a pharmaceutical composition containing, as active ingredients, a fusion protein dimer comprising an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor can be effectively applied to the treatment of cancer and has high industrial applicability.

Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an IL-2 mutant and a CD80 extracellular domain

A wrist-type body composition measuring apparatus is provided to measure body composition conveniently. The wrist-type body composition measuring apparatus includes a main body comprising a measurer configured to measure body impedance of a user, and an analyzer configured to analyze a body composition of the user based on the measured body impedance; a strap connected to the main body and configured to be flexible; a first inner electrode and a second inner electrode which are provided on a rear surface of the main body to be in direct contact with the user; and a first outer electrode and a second outer electrode which are provided on a surface of the main body to be in contact with the user during measurement of the body composition, wherein the first outer electrode and the second outer electrode are each formed as a half ring and face each other with a gap therebetween.

Wrist-type body composition measuring apparatus

An apparatus for health management includes an information collector configured to collect body composition information and characteristic information of a user, and a processor configured to determine a degree of muscle loss of the user based on the body composition information and the characteristic information of the user and provide a personalized health management program to the user based on the determined degree of muscle loss.

Apparatus and method for health management

An apparatus and method for measuring a bioelectric impedance is provided. The apparatus may measure the bioelectric impedance using three electrodes. The apparatus may measure the bioelectric impedance by compensating for a change of a contact impedance.

Apparatus and method for measuring bioelectric impedance using three-electrode sensor

There are provided an anti-c-Met/anti-Her2 bispecific antibody, and a method for preventing and/or treating cancer using the same.

Bispecific anti-Cmet/anti-Her2 antibodies

An anti-EGFR scFV fragment, an anti-c-Met/anti-EGFR bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same are provided.

Anti-EGFR antibody and anti-c-Met/anti-EGFR bispecific antibodies comprising the same

Pharmaceutical composition including a bispecific anti-c-Met/anti-EGFR antibody and a c-Src inhibitor and a method of preventing and/or treating cancer including co-administering a bispecific anti-c-Met/anti-EGFR antibody and a c-Src inhibitor to a subject in need thereof.

Combination therapy using bispecific anti-c-Met/anti-EGFR antibody and c-Src inhibitor

There are provided an anti-c-Met/anti-EGFR bispecific antibody, a method for treating cancer using the same, and an anti-EGFR scFv fragment.

Anti-c-Met/anti-EGFR bispecific antibodies

A method of target membrane protein depletion comprising treating a cell with a dual binding molecule comprising a first binding domain which binds to a driver membrane protein and a second binding domain which binds to a target membrane protein, wherein the cell comprises a cell membrane, and the driver membrane protein and target membrane protein are associated with the cell membrane where the target membrane protein positions, and are internalized into a cell and degraded when the first binding domain of the dual binding molecule binds the driver membrane protein; as well as related methods and compositions.

Method of target membrane protein depletion

A bispecific chimeric protein including a designed ankyrin repeat protein (DARPin), and an IgG antibody, an scFv-Fc antibody fragment, or a combination thereof, linked to the DARPin; a method for treating or preventing cancer using the same; and related methods and compositions.

Growing community of inventors

Yongin-si, South Korea

Young Jun Koh